
Opinion|Videos|January 17, 2025
Overview and Benefits of Port Delivery System with Ranibizumab
Panelists discuss how the port delivery system (PDS) with ranibizumab represents a paradigm shift in neovascular AMD treatment by utilizing a surgically implanted refillable device that provides continuous medication delivery for 6 months, offering patients a preferred alternative to frequent intravitreal injections while ensuring consistent therapeutic levels.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Can you provide an overview of the port delivery system with ranibizumab approved for treating neovascular AMD?
- How does the device function?
- What are the benefits of using the port delivery system with ranibizumab?
- Certainty of 6 months of continuous anti-VEGF delivery
- Patients in clinical trials prefer PDS over intravitreal injections
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Eichenbaum Acorns: From clinic to C-suite with Jay S. Duker, MD, and Ramiro Ribeiro, MD, PhD
2
Altered ipRGC circuits and function may translate to disrupted sleep and circadian rhythms in Alzheimer’s disease
3
Ranluspec FDA approval: Cyrus Karkaria, PhD, on biosimilar access, prefilled syringes, and long-term switching confidence
4
CTS 2026: OTX-TKI demonstrates superiority over aflibercept in wet AMD—what the SOL-1 data mean for retina practice
5





















